<DOC>
	<DOCNO>NCT01373710</DOCNO>
	<brief_summary>The purpose study : Phase I : To determine Trastuzumab maximum tolerate dose ( MTD ) weekly administrate intrathecal intraventricular route reach intra CSF target concentration ( 30 Âµg/mL ) near conventional therapeutic concentration depend dose-limiting toxicity ( DLT ) Phase II : Determination antitumor activity trastuzumab administrate IT intra-ventricular term neurological progression-free survival 2 month</brief_summary>
	<brief_title>Intrathecal Trastuzumab Administration Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis</brief_title>
	<detailed_description>Phase I : Secondary Outcome Measures : Recommended dose ( RD use Phase II ) Toxicity treatment Clinical response specific neurologic symptom Time neurologic progression Biological response : CSF cellularity protein concentration Radiological response : cerebrospinal meningitis neuraxis RMI Impact quality life Impact survival ( overall survival , survival without neurological progression , progression-free survival ) Pharmacokinetics : dose trastuzumab CSF plasma FCGR3A Genetic status influence efficacy trastuzumab metastatic breast cancer Phase II : Secondary Outcome Measures : Toxicity treatment Clinical response specific neurologic symptom Time neurologic progression Biological response : CSF cellularity protein concentration Radiological response : cerebrospinal meningitis neuraxis MRI Impact quality life Impact survival ( overall survival , survival without neurological progression , progression-free survival ) Pharmacokinetics : dose trastuzumab CSF plasma ( confirmation phase I data 5 patient ) FCGR3A Genetic status influence efficacy trastuzumab metastatic breast cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Metaplastic Infiltrating adenocarcinoma breast HER2 Overexpression IHC / amplification ( FISH ICHS ) Positive diagnosis neoplastic meningitis : positive CSF cytology ( obtain within 28 day inclusion ) AND / OR clinical symptom neoplastic meningitis aspect tumoral meningitis MRI Brain metastasis allow without prior treatment , asymptomatics without engagement . In case symptomatic brain metastasis , subject could include surgery / radiotherapy ( stereotactic toto ) perform cerebral metastatic localization allow IT intraventricular treatment . The last radiotherapy session surgery must do 3 week . Aged 18 year old Male female Life expectancy 2 month Satisfactory Cardiac function : leave ventricular ejection fraction ( LVEF ) determine ultrasound scan myocardial scintigraphy Adequate Biological function 14 day inclusion , accord criterion : Neutrophils &gt; 1.0 x 109/L , Hemoglobin &gt; 9.0 g/dL ( + transfusion need , Platelets &gt; 50 x 109/L , Bilirubin &lt; 3 x N , ALT &amp; AST &lt; 10 x N , Creatinine &lt; 2.0 mg/dL , Clearance &gt; 25 mL/min ( Cockcroft Gault formula ) , Prothrombin time &gt; 70 % , Kaolin cephalin coagulation time &lt; 1.5 x N. Women childbearing potential , must take adequate birth control measure study period must negative pregnancy test ( BetaHCG serum ) The subject must perform evaluation preinclusion , provide protocol Signed write inform consent CSF circulation disorder suspect MRI brain ( obstructive hydrocephalus ) medullar ( obstacle ) , case focal radiotherapy obstructive lesion , check restoration transit traffic isotope CSF Anticoagulant effective dose treatment trastuzumab administration lumbar puncture Patient Lapatinib ( wash &gt; 2 week date first dose intrathecal trastuzumab ) Known suspect trastuzumab allergy Contraindications trastuzumab administration , include cardiac disease : LVEF &lt; laboratory lower limit normal heart condition would expose subject unreasonable risk participate study Severe toxicity unresolved unstable related another previous study restrict drug / cancer treatment Ventriculoperitoneal atrial shunting except valve could turn ( onoff switch ) patient stand 6 h injection trastuzumab Dementia , alter mental status psychiatric condition would prevent subject understand give inform consent Preexisting severe cerebrovascular disease , stroke major vessel , vasculitis central nervous system malignant hypertension Uncontrolled infection Participation clinical study experimental molecule No affiliation Social insurance ( beneficiary assignee ) Pregnant woman , breastfeed childbearing age take contraceptive Subject unable make follow schedule Persons deprive liberty guardianship ( include curator )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adverse Reaction Trastuzumab Administered intrathecal</keyword>
</DOC>